{"id":68772,"date":"2026-02-21T15:51:18","date_gmt":"2026-02-21T15:51:18","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=68772"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"retatrutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/retatrutide\/","title":{"rendered":"Retatrutid\u0103"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u0103spuns rapid \u2014 Ce este Retatrutida?<\/h3>\n<p style=\"margin: 0;\">Retatrutida (LY3437943) este un peptid de cercetare \u0219i primul <strong>agonist triplu de receptori<\/strong> care ac\u021bioneaz\u0103 simultan asupra receptorilor GLP-1, GIP \u0219i glucagon \u00eentr-o singur\u0103 molecul\u0103. \u00cen studiile de faz\u0103 2 (Jastreboff 2023, NEJM) a produs o sc\u0103dere medie a greut\u0103\u021bii de <strong>24,2% la 48 de s\u0103pt\u0103m\u00e2ni<\/strong> \u2014 mai mare dec\u00e2t orice alt peptid metabolic publicat p\u00e2n\u0103 acum. Disponibil \u00een vile liofilizate de la 5 mg p\u00e2n\u0103 la 60 mg, strict pentru uz \u00een cercetare laboratorial\u0103.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Peptide liofilizate pentru cercetare \u00b7 puritate HPLC \u226599% (certificat de analiz\u0103 la cerere) \u00b7 Ambalaj discret stabil la temperatur\u0103 \u00b7 Curierat worldwide de peptide \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifica\u021bii<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detaliu<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u0103r CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2381089-83-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formula molecular\u0103<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>221<\/sub>H<sub>342<\/sub>N<sub>46<\/sub>O<sub>68<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Greutate molecular\u0103<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4731.4 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secven\u021b\u0103<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agonist triplu modificat GIP\/GLP-1\/GCGR (39 de reziduuri, lipidat; formul\u0103 proprietar\u0103 Lilly LY-3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Form\u0103<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pulbere liofilizat\u0103 (sau a\u0219a cum este furnizat)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puritate<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificat prin HPLC, COA la cerere)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Depozitare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizat: 2\u20138\u00b0C (frigider) pentru stocul de lucru; \u221220\u00b0C pentru depozitarea pe termen lung a vialelor nefolosite. Reconstituit: 2\u20138\u00b0C, utilizat \u00een ~30 de zile. Proteja\u021bi de lumin\u0103. Nu \u00eenghe\u021ba\u021bi-decongela\u021bi solu\u021bia reconstituit\u0103.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilitate<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Ap\u0103 bacteriostatic\u0103 (recomandat\u0103) sau ap\u0103 steril\u0103 pentru perioade mai scurte de utilizare<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Utilizare \u00een cercetare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Doar pentru utilizare \u00een cercetare de laborator. Nu este destinat pentru uz diagnostic sau terapeutic uman sau veterinar.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Ce este Retatrutide<\/h2>\n<p><strong>Retatrutid\u0103<\/strong> (denumire investiga\u021bional\u0103 <strong>LY3437943<\/strong>) este un peptid sintetic de 39 de aminoacizi dezvoltat de Eli Lilly ca prim agonist triplu \u00een stadiul clinic al receptorilor GLP-1, GIP \u0219i glucagon. \u00cen timp ce peptidele incretine anterioare ac\u021bioneaz\u0103 pe un singur receptor (semaglutid\u0103 \u2014 GLP-1) sau dou\u0103 (tirzepatid\u0103 \u2014 GLP-1 plus GIP), retatrutida activeaz\u0103 simultan to\u021bi cei trei receptori metabolici. Aceast\u0103 farmacologie distinct\u0103 este studiat\u0103 pentru obezitate, diabet zaharat de tip 2, boal\u0103 hepatic\u0103 gras\u0103 non-alcoolic\u0103 (NAFLD\/MASH) \u0219i sindromul metabolic asociat hipertensiunii.<\/p>\n<p>Peptidul are o greutate molecular\u0103 de aproximativ 4.731,4 Da, formula empiric\u0103 C<sub>221<\/sub>H<sub>342<\/sub>N<sub>46<\/sub>O<sub>68<\/sub>, \u0219i este furnizat sub form\u0103 de pulbere liofilizat\u0103 de \u00eenalt\u0103 puritate pentru reconstituire cu ap\u0103 bacteriostatic\u0103. Este <strong>destinat doar pentru cercetare de laborator<\/strong> \u0219i nu este destinat pentru diagnostic sau terapie uman\u0103 sau veterinar\u0103. Pentru detalii mai profunde despre mecanism, studii \u0219i perspective, consulta\u021bi ghidul nostru complet <a href=\"https:\/\/medsbase.com\/ro\/retatrutide-triple-agonist-weight-loss-guide\/\">Ghid de cercetare Retatrutide<\/a>.<\/p>\n<h2>Mecanism de ac\u021biune \u2014 Agonist triplu GLP-1\/GIP\/Glucagon<\/h2>\n<p>Profilul receptor al retatrutidei este ceea ce o diferen\u021biaz\u0103 de orice alt peptid metabolic disponibil pe pia\u021b\u0103 sau \u00een studii avansate. Fiecare dintre cei trei receptori contribuie cu o cale distinct\u0103 la efectele observate asupra compozi\u021biei corporale, controlului glicemic \u0219i echilibrului energetic:<\/p>\n<ul>\n<li><strong>Receptor GLP-1<\/strong> \u2014 acela\u0219i receptor activat de semaglutid\u0103 (Ozempic, Wegovy) \u0219i liraglutid\u0103. Agonismul \u00eencetine\u0219te golirea gastric\u0103, intensific\u0103 semnalizarea sa\u021biet\u0103\u021bii \u00een hipotalamus \u0219i stimuleaz\u0103 secre\u021bia de insulin\u0103 dependent\u0103 de glucoz\u0103 din celulele beta pancreatice.<\/li>\n<li><strong>Receptor GIP<\/strong> \u2014 a doua cale ad\u0103ugat\u0103 de tirzepatid\u0103 (Mounjaro, Zepbound). Agonismul GIP \u00eembun\u0103t\u0103\u021be\u0219te sensibilitatea la insulin\u0103 \u00een \u021besutul adipos, reduce plafonul de grea\u021b\u0103 al GLP-1 singur \u0219i sprijin\u0103 eficien\u021ba gestion\u0103rii lipidelor \u00een adipocite.<\/li>\n<li><strong>Receptor glucagon<\/strong> \u2014 noua a treia cale unic\u0103 pentru retatrutid. Agonismul glucagonului cre\u0219te cheltuiala energetic\u0103 bazal\u0103, promoveaz\u0103 oxidarea lipidic\u0103 hepatic\u0103 \u0219i reduce gr\u0103simea din ficat \u2014 efecte pe care duo-ul GLP-1\/GIP nu le reproduce.<\/li>\n<\/ul>\n<p>Deoarece cre\u0219terea cheltuielii energetice prin glucagon se adaug\u0103 peste suprimarea apetitului determinat\u0103 de GLP-1\/GIP, retatrutida produce at\u00e2t un deficit energetic mai mare, c\u00e2t \u0219i un profil mai favorabil al compozi\u021biei corporale \u00een modelele preclinice, comparativ cu peptidele dual-agoniste. \u00cen datele cercet\u0103rii de faz\u0103 2, pierderea masei grase a reprezentat majoritatea reducerii totale \u00een greutate, cu men\u021binerea masei magre la dozele mai mari.<\/p>\n<h2>Date Publicate din Studii<\/h2>\n<p>Setul principal de date pentru retatrutid\u0103 provine din studiul de faz\u0103 2 pentru obezitate publicat de Jastreboff \u0219i colegii \u00een <em>New England Journal of Medicine<\/em> \u00een iunie 2023 (n=338 participan\u021bi cu obezitate, perioad\u0103 de tratament de 48 de s\u0103pt\u0103m\u00e2ni). La cea mai mare doz\u0103 testat\u0103 de 12 mg s\u0103pt\u0103m\u00e2nal, participan\u021bii au \u00eenregistrat o reducere medie a greut\u0103\u021bii corporale de <strong>24,2% fa\u021b\u0103 de valoarea ini\u021bial\u0103<\/strong>. Bra\u021bul cu semaglutid\u0103 din studiul STEP-1 a produs o reducere de 14,9% la 68 de s\u0103pt\u0103m\u00e2ni, iar bra\u021bul cu tirzepatid\u0103 din SURMOUNT-1 a produs 22,5% la 72 de s\u0103pt\u0103m\u00e2ni \u2014 astfel, retatrutida a ob\u021binut o reducere numeric mai mare \u00eentr-o perioad\u0103 de tratament mai scurt\u0103. Studii comparative directe nu au fost \u00eenc\u0103 publicate.<\/p>\n<p>Un program paralel de faz\u0103 2 pentru diabet (Rosenstock et al., <em>Lancet<\/em> 2023) a demonstrat reduc\u021bii ale HbA1c de p\u00e2n\u0103 la 2,16 puncte procentuale la 36 de s\u0103pt\u0103m\u00e2ni la participan\u021bii cu diabet zaharat de tip 2, din nou la doza s\u0103pt\u0103m\u00e2nal\u0103 de 12 mg. Un sub-studiu de faz\u0103 2 pentru NAFLD a raportat o reducere relativ\u0103 a con\u021binutului de gr\u0103sime hepatic\u0103 de 51,3% dup\u0103 24 de s\u0103pt\u0103m\u00e2ni la doza de 8 mg \u2014 cea mai mare reducere a gr\u0103simii hepatice raportat\u0103 pentru orice peptid din clasa incretinelor p\u00e2n\u0103 \u00een prezent.<\/p>\n<p>Eli Lilly deruleaz\u0103 \u00een prezent programul de faz\u0103 3 TRIUMPH, care include <strong>TRIUMPH-1<\/strong> (obezitate), <strong>TRIUMPH-2<\/strong> (obezitate cu diabet zaharat de tip 2), <strong>TRIUMPH-3<\/strong> (obezitate cu boli cardiovasculare) \u0219i <strong>TRIUMPH-4<\/strong> (apnee \u00een somn plus obezitate). Rezultatele din faza 3 sunt a\u0219teptate s\u0103 contribuie la depunerea ulterioar\u0103 pentru aprobare regulatorie.<\/p>\n<h2>Aplica\u021bii de cercetare<\/h2>\n<p>Retatrutid este utilizat \u00een contexte de cercetare de laborator care investigheaz\u0103:<\/p>\n<ul>\n<li><strong>Obezitatea \u0219i reglarea greut\u0103\u021bii corporale<\/strong> \u2014 studii mecanistice privind semnalizarea apetitului, cinetica golirii gastrice \u0219i cheltuiala energetic\u0103 \u00een modele pe roz\u0103toare \u0219i in vitro<\/li>\n<li><strong>Sensibilitatea la insulin\u0103 \u0219i homeostazia glucozei<\/strong> \u2014 efecte asupra secre\u021biei de insulin\u0103, produc\u021biei hepatice de glucoz\u0103 \u0219i elimin\u0103rii periferice a glucozei<\/li>\n<li><strong>Steatoz\u0103 hepatic\u0103 \/ MASH<\/strong> \u2014 mobilizarea gr\u0103simii hepatice \u0219i r\u0103spunsul transaminazelor \u00een modelele de cercetare ale ficatului gras<\/li>\n<li><strong>Farmacologie receptorilor<\/strong> \u2014 studii comparative de legare, selectivitate \u0219i semnalizare downstream pe triada de receptori GLP-1\/GIP\/glucagon<\/li>\n<li><strong>Cercetare comparativ\u0103 a peptidelelor metabolice<\/strong> \u2014 compararea cu tirzepatida (agonist dual GLP-1\/GIP) \u0219i alte compu\u0219i investiga\u021bionali \u00een ceea ce prive\u0219te poten\u021ba, tolerabilitatea \u0219i rezultatele privind compozi\u021bia corporal\u0103. Consulta\u021bi <a href=\"https:\/\/medsbase.com\/ro\/tirzepatide-tirzepatide-vs-semaglutide\/\">compararea tirzepatid\u0103 vs semaglutid\u0103<\/a> pentru linia de baz\u0103 a agonistului dual.<\/li>\n<li><strong>Suprapunere de peptide pentru vindecare \u0219i recuperare<\/strong> \u2014 protocoale de cercetare care asociaz\u0103 peptidele metabolice cu compu\u0219i de reparare precum <a href=\"https:\/\/medsbase.com\/ro\/bpc-157\/\">BPC-157<\/a> \u00een studii preclinice.<\/li>\n<\/ul>\n<p>Pentru un context mai larg privind locul retatrutidei \u00een peisajul peptidelelor pentru pierderea \u00een greutate, consulta\u021bi <a href=\"https:\/\/medsbase.com\/ro\/peptide-stacks-for-fat-loss\/\">ghidul nostru despre stivele de peptide pentru cercetarea pierderii de gr\u0103sime<\/a> \u0219i <a href=\"https:\/\/medsbase.com\/ro\/glp-1-weight-loss-injections-guide\/\">ghidul general al injec\u021biilor GLP-1 pentru pierderea \u00een greutate<\/a>. R\u0103sfoi\u021bi catalogul complet <a href=\"https:\/\/medsbase.com\/ro\/peptides\/\">de peptide de cercetare<\/a> pentru compu\u0219i \u00eenrudi\u021bi.<\/p>\n<h2>Concentra\u021bii \u0219i doze disponibile<\/h2>\n<p>MedsBase ofer\u0103 retatrutide \u00een urm\u0103toarele formate de flacoane liofilizate. Fiecare variant\u0103 este disponibil\u0103 \u00een pachete de 10 \u0219i 20 de flacoane, expediate \u00een condi\u021bii refrigerate cu instruc\u021biuni de reconstituire:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Putere flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caz de utilizare tipic<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dimensiuni pachet<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Studii pilot de dozare, ramp\u0103 de titrare<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 sau 20 flacoane<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Concentra\u021bie standard de cercetare, cea mai comandat\u0103<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 sau 20 flacoane<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Doza de prob\u0103 corespunz\u0103toare (faza 2, bra\u021bul cu doz\u0103 mare)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 sau 20 flacoane<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocoale de cercetare extinse, preparare \u00een vrac<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 sau 20 flacoane<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>30 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cercetare \u00een vrac (mai pu\u021bine reconstituiri pe protocol)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 sau 20 flacoane<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cercetare de mare productivitate, optimizare a costului pe mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 sau 20 flacoane<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Utilizare \u00een laborator pentru loturi mari<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 sau 20 flacoane<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>60 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Op\u021biunea maxim\u0103 \u00een vrac, cercetare de cea mai lung\u0103 durat\u0103<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 sau 20 flacoane<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Toate concentra\u021biile sunt furnizate \u00een aceea\u0219i form\u0103 chimic\u0103 (pulbere liofilizat\u0103, puritate HPLC \u226599%). Flacoanele cu doze mai mari ofer\u0103 un cost pe mg mai mic, dar necesit\u0103 volume mai mici de reconstituire pentru a men\u021bine concentra\u021biile standard \u00een seringile U-100 \u2014 consulta\u021bi tabelul de dilu\u021bie de mai jos.<\/p>\n<h2>Compara\u021bie \u2014 Retatrutid\u0103 vs Tirzepatid\u0103 vs Semaglutid\u0103<\/h2>\n<p>Rezumatul urm\u0103tor se bazeaz\u0103 pe datele publicate din studii. Retatrutida este \u00eenc\u0103 \u00een faza 3 de dezvoltare, iar compara\u021biile de mai jos provin din studii separate, nu din studii comparative directe.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criteriu<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutid\u0103<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tirzepatide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u021ainte receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + Glucagon (triplu)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP (dublu)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (simplu)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Pierdere maxim\u0103 de greutate publicat\u0103<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">24,2% la 48 s\u0103pt.<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">22,5% la 72 s\u0103pt.<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">14,9% la 68 s\u0103pt.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Frecven\u021ba administr\u0103rii<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u0103pt\u0103m\u00e2nal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u0103pt\u0103m\u00e2nal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u0103pt\u0103m\u00e2nal<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Statut de reglementare<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Faza 3 (TRIUMPH) \u2014 investiga\u021bional<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aprobat de FDA (Mounjaro\/Zepbound)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aprobat de FDA (Ozempic\/Wegovy)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Reducerea gr\u0103simii hepatice<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">51,3% la 24 s\u0103pt. (faza 2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~47% la 52 s\u0103pt.<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~31% la 72 s\u0103pt.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Reducere HbA1c (DT2)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u00e2n\u0103 la -2,16% la 36 s\u0103pt.<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u00e2n\u0103 la -2,3% la 40 s\u0103pt.<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u00e2n\u0103 la -1,8% la 40 de s\u0103pt\u0103m\u00e2ni<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Pentru o compara\u021bie mai detaliat\u0103 \u00eentre tirzepatide \u0219i semaglutide, consulta\u021bi <a href=\"https:\/\/medsbase.com\/ro\/tirzepatide-tirzepatide-vs-semaglutide\/\">Tirzepatide vs Semaglutide: Pierdere \u00een greutate, dozare \u0219i cost<\/a>.<\/p>\n<h2>Depozitare \u0219i reconstituire<\/h2>\n<p><strong>\u00cenainte de reconstituire:<\/strong> depozita\u021bi flacoanele liofilizate la frigider la 2\u20138 \u00b0C \u00een ambalajul original din folie. \u00cen aceste condi\u021bii, retatrutida liofilizat\u0103 r\u0103m\u00e2ne stabil\u0103 p\u00e2n\u0103 la 36 de luni. Evita\u021bi ciclurile repetate de temperatur\u0103.<\/p>\n<p><strong>Procedura de reconstituire:<\/strong> ad\u0103uga\u021bi ap\u0103 bacteriostatic\u0103 \u00een flaconul cu peptid\u0103 conform tabelului de dilu\u021bie de mai sus. Injecta\u021bi apa pe peretele lateral al flaconului \u0219i nu direct pe tortul liofilizat. \u00cenv\u00e2rti\u021bi u\u0219or \u2014 nu <strong>prime\u0219te,<\/strong> agita\u021bi \u2014 \u0219i l\u0103sa\u021bi 5\u201310 minute pentru dizolvare complet\u0103. Solu\u021bia reconstituit\u0103 complet ar trebui s\u0103 fie clar\u0103 \u0219i incolor\u0103.<\/p>\n<p><strong>Dup\u0103 reconstituire:<\/strong> depozita\u021bi solu\u021bia la frigider la 2\u20138 \u00b0C \u0219i utiliza\u021bi-o \u00een termen de 30 de zile pentru stabilitate optim\u0103. Nu \u00eenghe\u021ba\u021bi solu\u021bia reconstituit\u0103 \u2014 ciclurile de \u00eenghe\u021bare-dezghe\u021bare degradeaz\u0103 integritatea peptidelor. Arunca\u021bi orice flacon care prezint\u0103 tulbureal\u0103, precipitat sau decolorare.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3>Pentru ce este utilizat retatrutide \u00een cercetare?<\/h3>\n<p>Retatrutide este utilizat \u00een cercet\u0103rile de laborator care investigheaz\u0103 obezitatea, diabetul de tip 2, boala hepatic\u0103 gras\u0103 non-alcoolic\u0103 (NAFLD\/MASH), sensibilitatea la insulin\u0103, reglarea apetitului \u0219i farmacologia comparativ\u0103 a peptidelor metabolice. Nu este <strong>prime\u0219te,<\/strong> aprobat de FDA, EMA sau alte autorit\u0103\u021bi de reglementare pentru uz terapeutic uman \u0219i este v\u00e2ndut aici strict pentru uz \u00een cercetare de laborator.<\/p>\n<h3>Cum difer\u0103 retatrutide de tirzepatide \u0219i semaglutide?<\/h3>\n<p>Retatrutide este primul agonist triplu de receptori, care se leag\u0103 de receptorii GLP-1, GIP, <em>\u0219i<\/em> glucagon \u00eentr-o singur\u0103 molecul\u0103. Tirzepatide se leag\u0103 de GLP-1 \u0219i GIP (dual). Semaglutide se leag\u0103 doar de GLP-1 (simplu). Calea adi\u021bional\u0103 a glucagonului \u00een retatrutide cre\u0219te cheltuiala energetic\u0103 \u0219i reduce gr\u0103simea hepatic\u0103 \u00een moduri pe care agonii duali \u0219i simpli nu le reproduc.<\/p>\n<h3>Ce pierdere \u00een greutate a demonstrat retatrutide \u00een studii?<\/h3>\n<p>Studiul de faz\u0103 2 pentru obezitate publicat de Jastreboff et al. \u00een NEJM (2023) a raportat o reducere medie a greut\u0103\u021bii corporale de 24,2% la 48 de s\u0103pt\u0103m\u00e2ni la cea mai mare doz\u0103 testat\u0103 de 12 mg s\u0103pt\u0103m\u00e2nal. Pentru context, doza cea mai mare de tirzepatide \u00een faza 3 a produs o reducere de 22,5% la 72 de s\u0103pt\u0103m\u00e2ni, iar semaglutide a produs 14,9% la 68 de s\u0103pt\u0103m\u00e2ni. Rezultatele din faza 3 pentru retatrutide din programul TRIUMPH sunt \u00een a\u0219teptare.<\/p>\n<h3>Este retatrutide aprobat de FDA?<\/h3>\n<p>Nu. Retatrutide se afl\u0103 \u00een prezent \u00een dezvoltare clinic\u0103 de faz\u0103 3 \u00een cadrul programului TRIUMPH al Eli Lilly \u0219i nu a primit aprobare reglementar\u0103 de la FDA, EMA, MHRA sau orice alt\u0103 autoritate. Peptidul v\u00e2ndut de furnizori doar pentru cercetare este destinat investiga\u021biilor de laborator, nu pentru uz terapeutic uman.<\/p>\n<h3>Ce doze stocheaz\u0103 MedsBase?<\/h3>\n<p>MedsBase comercializeaz\u0103 retatrutide \u00een flacoane liofilizate de 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg \u0219i 60 mg. Fiecare doz\u0103 este disponibil\u0103 \u00een ambalaje de 10 sau 20 de flacoane. Toate flacoanele sunt furnizate cu o puritate HPLC de 99%+, cu certificat de analiz\u0103 la cerere.<\/p>\n<h3>Cum se reconstituie retatrutide?<\/h3>\n<p>Urma\u021bi tabelul de diluare de mai sus. Un flacon de 10 mg cu 2,0 mL de ap\u0103 bacteriostatic\u0103 produce 5,0 mg\/mL, deci 40 de diviziuni pe o sering\u0103 de insulin\u0103 U-100 (1 mL \/ 100 unit\u0103\u021bi) echivaleaz\u0103 cu 2 mg. Injecta\u021bi apa BAC pe peretele lateral, amesteca\u021bi u\u0219or (nu agita\u021bi) \u0219i l\u0103sa\u021bi 5\u201310 minute pentru dizolvare \u00eenainte de utilizare.<\/p>\n<h3>Cum trebuie stocat retatrutide?<\/h3>\n<p>Flacoane liofilizate: la frigider la 2\u20138 \u00b0C \u00een ambalajul original, stabil p\u00e2n\u0103 la 36 de luni. Solu\u021bia reconstituit\u0103: la frigider la 2\u20138 \u00b0C, utilizat\u0103 \u00een termen de 30 de zile. Nu \u00eenghe\u021ba\u021bi solu\u021bia reconstituit\u0103 \u2014 ciclurile de \u00eenghe\u021bare-dezghe\u021bare degradeaz\u0103 peptidul.<\/p>\n<h3>Care este doza tipic\u0103 de cercetare a retatrutidei \u00een studii?<\/h3>\n<p>Bra\u021bele studiului de faz\u0103 2 pentru obezitate au testat doze s\u0103pt\u0103m\u00e2nale de 1 mg, 4 mg, 8 mg \u0219i 12 mg pe parcursul a 48 de s\u0103pt\u0103m\u00e2ni. R\u0103spunsul la pierderea \u00een greutate a fost dependent de doz\u0103, cu o reducere de 24,2% observat\u0103 la doza de 12 mg. Protocoalele de cercetare de laborator reflect\u0103 de obicei aceste doze din studii atunci c\u00e2nd inten\u021bia este de a modela datele de eficacitate publicate.<\/p>\n<h3>Retatrutide provoac\u0103 acelea\u0219i efecte secundare ca \u0219i alte peptide GLP-1?<\/h3>\n<p>\u00cen studiile publicate, cele mai frecvente evenimente ap\u0103rute \u00een urma tratamentului au fost efecte gastrointestinale dependente de doz\u0103 \u2014 grea\u021b\u0103, diaree, constipa\u021bie \u2014 cu un profil similar celor observate la semaglutid\u0103 \u0219i tirzepatid\u0103. Activitatea suplimentar\u0103 la nivelul receptorului de glucagon nu a produs semnale de siguran\u021b\u0103 nea\u0219teptate \u00een faza 2, dar profilul complet de tolerabilitate a\u0219teapt\u0103 rezultatele din faza 3.<\/p>\n<h3>C\u00e2t timp va dura p\u00e2n\u0103 c\u00e2nd retatrutida va fi aprobat\u0103 de FDA?<\/h3>\n<p>Programul de faz\u0103 3 TRIUMPH al Eli Lilly a \u00eenceput \u00eenregistrarea pacien\u021bilor \u00een perioada 2023\u20132024, cu date primare de finalizare estimate pentru 2025\u20132027, \u00een func\u021bie de sub-studii. Presupun\u00e2nd rezultate pozitive, o trimitere c\u0103tre FDA ar putea urma la 12\u201318 luni dup\u0103 finalizarea principal\u0103. Termenele de aprobare reglementar\u0103 sunt speculative p\u00e2n\u0103 c\u00e2nd Lilly va anun\u021ba depunerea dosarului.<\/p>\n<h3>Care este timpul de \u00eenjum\u0103t\u0103\u021bire al Retatrutidei?<\/h3>\n<p>Retatrutida (LY3437943) are un timp de \u00eenjum\u0103t\u0103\u021bire lung de eliminare de aproximativ 6 zile conform datelor clinice din Faza I, atribuit modific\u0103rii cu acid gras C18 care permite legarea de albumin\u0103. Acest timp de \u00eenjum\u0103t\u0103\u021bire extins sus\u021bine regimurile de administrare o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103 utilizate \u00een studiile clinice.<\/p>\n<h3>Cum se compar\u0103 Retatrutida cu Tirzepatida \u0219i Semaglutida?<\/h3>\n<p>Retatrutida este un agonist triplu (receptori GLP-1 \/ GIP \/ Glucagon), comparativ cu agonismul dublu al Tirzepatidei (GLP-1 \/ GIP) \u0219i agonismul unic al Semaglutidei (GLP-1). Datele din studiile clinice de faz\u0103 II pentru Retatrutid\u0103 au raportat o reducere a greut\u0103\u021bii de p\u00e2n\u0103 la 24% la 48 de s\u0103pt\u0103m\u00e2ni \u2014 dep\u0103\u0219ind rezultatele at\u00e2t pentru Tirzepatid\u0103, c\u00e2t \u0219i pentru Semaglutid\u0103 \u00een perioade comparabile. Se crede c\u0103 activitatea suplimentar\u0103 la nivelul receptorului de glucagon determin\u0103 o cheltuial\u0103 energetic\u0103 mai mare \u0219i o oxidare mai intens\u0103 a gr\u0103similor.<\/p>\n<h3>Pot comanda retatrutid\u0103 pentru transport interna\u021bional?<\/h3>\n<p>Da. MedsBase expediaz\u0103 retatrutid\u0103 \u00een \u00eentreaga lume prin re\u021beaua noastr\u0103 dedicat\u0103 de transport de peptide. Comenzile care con\u021bin doar peptide se calific\u0103 pentru serviciul nostru independent de transport de peptide. Comenzile sunt expediate \u00een ambalaje cu control al temperaturii \u0219i cu urm\u0103rire complet\u0103.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Alte peptide pentru cercetare \u00een recuperare \u0219i performan\u021b\u0103<\/h2>\n<ul>\n<li><a href=\"\/ro\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Compus de protec\u021bie corporal\u0103 \u2014 cercetare \u00een recuperarea tendonilor, ligamentelor \u0219i intestinului<\/li>\n<li><a href=\"\/ro\/tb-500\/\"><strong>TB-500<\/strong><\/a> \u2014 Fragment de Thymosin Beta-4 \u2014 cercetare \u00een recuperarea \u021besuturilor moi \u0219i vasculare<\/li>\n<li><a href=\"\/ro\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Agonist selectiv de ghrelin\u0103 \u2014 puls de hormon de cre\u0219tere f\u0103r\u0103 cortizol\/prolactin\u0103<\/li>\n<li><a href=\"\/ro\/cjc-1295-with-dac\/\"><strong>CJC-1295 cu DAC<\/strong><\/a> \u2014 Analog GHRH cu timp de \u00eenjum\u0103t\u0103\u021bire prelungit<\/li>\n<li><a href=\"\/ro\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Peptid de cupru \u2014 cercetare \u00een regenerarea pielii \u0219i a \u021besutului conjunctiv<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lectur\u0103 suplimentar\u0103<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Afla\u021bi cercetarea din spatele acestui peptid<\/strong><\/p>\n<p style=\"margin: 0;\">Cititi ghidul nostru complet bazat pe dovezi: <a href=\"https:\/\/medsbase.com\/ro\/retatrutide-triple-agonist-weight-loss-guide\/\"><strong>Retatrutid\u0103 \u2014 mecanism, date din studii \u0219i perspective<\/strong><\/a>. Acoper\u0103 mecanismul de ac\u021biune, datele din studiile publicate, gamele tipice de dozare pentru cercetare, protocoale de reconstituire, considera\u021bii de combinare \u0219i note de siguran\u021b\u0103\/contraindica\u021bii.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Sus\u021bine pierderea s\u0103n\u0103toas\u0103 \u00een greutate \u0219i \u00eembun\u0103t\u0103\u021be\u0219te func\u021bia metabolic\u0103<br data-start=\"62\" data-end=\"65\" \/>\u2705 Ajut\u0103 la reglarea balan\u021bei energetice pentru o performan\u021b\u0103 zilnic\u0103 mai bun\u0103<br data-start=\"125\" data-end=\"128\" \/>\u2705 Promoveaz\u0103 arderea \u00eembun\u0103t\u0103\u021bit\u0103 a gr\u0103similor \u0219i eficien\u021ba metabolic\u0103<br data-start=\"184\" data-end=\"187\" \/>\u2705 Asist\u0103 \u00een controlul apetitului \u0219i reducerea poftelor de m\u00e2ncare<br data-start=\"239\" data-end=\"242\" \/>\u2705 \u00cencurajeaz\u0103 rezultate mai bune \u00een managementul general al greut\u0103\u021bii<\/p>\n<p><strong>Retatrutid\u0103<\/strong> con\u021bine compus peptidic sintetic.<\/p>","protected":false},"featured_media":70975,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5445,5444,5447,5446],"class_list":{"0":"post-68772","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-ly3437943","8":"product_tag-retatrutide","9":"product_tag-triple-agonist","10":"product_tag-triple-g","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/68772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=68772"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/70975"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=68772"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=68772"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=68772"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=68772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}